Pancreatic neuroendocrine tumors: VIPoma
What is the treatment of the VIPoma?
The first course of action once VIPoma has been diagnosed is to aggressively correct the dehydration and metabolic derangements which are often associated with the tumor. Octreotide can stop the diarrhea and allow for the correction of hypokalemia and other metabolic abnormalities in the majority of these patients. Once the fluid and electrolyte status has been normalized, surgical exploration is warranted for nearly all these patients. For those patients with no evidence of nodal or hepatic metastases, complete resection is the only chance for complete cure. Even for those patients with preoperative or intraoperative evidence of metastasis, surgical debulking can assist with postoperative medical management of residual disease. Postoperatively, octreotide can minimize symptoms of VIP hypersecretion in most patients with residual disease for some time until resistance develops.